ClinicalTrials.gg
CompletedNCT01540409Updated Mar 30, 2020Results posted

Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy

A Phase 2 interventional study of AVI-4658 (Eteplirsen) in Duchenne Muscular Dystrophy (DMD), sponsored by Sarepta Therapeutics, Inc.. Completed at 11 sites in United States. Open to male participants aged 7 Years to 13 Years. Per ClinicalTrials.gov, last updated 2020-03-30.

Sponsored by Sarepta Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
7 Years to 13 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.

Enrollment
8th of 11
12 · median 15
Started
2012
the only one that year
Phase 2
7 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
9 of 11
Sarepta Therapeutics, Inc.

Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 7 in phase 2, and was the 4th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →

About eteplirsen

eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 7 Years to 13 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne as a file.
02

Study summary

The primary objective of this study is to assess the ongoing efficacy, safety, and tolerability of an additional 212 weeks of treatment with eteplirsen injection in Duchenne muscular dystrophy (DMD) subjects who have successfully completed the 28 week eteplirsen study: Study 4658-us-201. This study will also evaluate the correlation between biomarkers for DMD and the clinical status of participating DMD subjects.

Read the detailed description

This is an open label, multiple dose extension study to assess the ongoing efficacy, safety, and tolerability of weekly intravenous (IV) infusions of eteplirsen in DMD subjects who have successfully completed Study 4658-us 201.

Subjects will have the opportunity to enroll in this study during the last visit of Study 4658-us-201 (Week 28). Eligible subjects will receive once weekly IV infusions of eteplirsen (50 or 30 mg/kg) for an additional 212 weeks. Subjects will receive the same dose of eteplirsen they received in Study 4658-us-201. Subjects will thereafter continue to receive once weekly IV infusions of eteplirsen for up to an additional 72 week period (through week 284). If commercial eteplirsen becomes available during this additional 72 week period, participation in the study will be discontinued as subjects transition to commercial eteplirsen.

Safety, efficacy, pharmacokinetic (PK), and biomarker assessments will be performed at scheduled visits; adverse events (AEs) and concomitant medications and therapies will be continuously monitored.

If review of data from this open label study suggests that continued treatment with eteplirsen is warranted, this study may be extended by protocol amendment or subjects who successfully complete this study may have the opportunity to participate in a separate follow on, open label eteplirsen study.

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)

Keywords

  • DMD, Duchenne, Eteplirsen, dystrophy, dystrophin, exon 51
04

Who can participate

Ages eligible
7 Years to 13 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject must meet all of the following criteria to be eligible for this study.

  1. The subject and/or their parent/legal guardian are willing and able to provide signed .
  2. The subject has successfully completed 28 weeks of treatment in Study 4658-US-201.
  3. The subject has a parent(s) or legal guardian(s) who is able to understand and comply with all of the study procedure requirements.

Exclusion criteria

Exclusion Criteria:

A subject who meets any of the following criteria will be excluded from this study.

  1. The subject has a prior or ongoing medical condition that, in the Investigator's opinion, could adversely affect the safety of the subject or make it unlikely that the course of treatment or follow-up would be completed or impair the assessment of study results.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    AVI-4658 (Eteplirsen)

    Multiple-Dose Extension Study

    Drug: AVI-4658 (Eteplirsen)

Interventions

  • DrugEteplirsenStudies of EteplirsenEteplirsen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.

    Also known as: EXONDYS 51

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the 6 Minute Walk Test (6MWT) at Week 240

    This study used a modified version of the 6MWT test procedure described in American Thoracic Society (ATS) 2002 guidelines, specifically adapted for patients with Duchenne muscular dystrophy. The participant was asked to walk a set course of 25 meters for 6 minutes (timed) and the distance walked in meters was recorded. Increases from baseline in 6MWT distance are indicative of improvement and decreases from baseline indicate worsening. Baseline here corresponds to the baseline in the parent study (4658-us-201, NCT01396239).

    Time frame: Parent Baseline and Week 240

  2. Change From Baseline in the Percentage of Dystrophin Positive Fibers (PDPF) at Week 48

    Dystrophin expression as assessed by percent dystrophin positive fibers was measured by immunohistochemistry (IHC) technique using primary anti-dystrophin antibody. Percent change from baseline is the arithmetic difference of the treatment time point minus baseline divided by baseline calculated for individual subjects. Baseline here corresponds to the baseline in the parent study (4658-us-201, NCT01396239).

    Time frame: Parent Baseline and Week 48

07

Results

Posted Jul 10, 2019

Participant flow

The study was conducted at 12 centers in the United States. Overall, 12 participants who completed parent study 4658-us-201 (NCT01396239) were enrolled between July 2011 and February 2012 in this extension study (4658-us-202; NCT01540409). A 4-week open label period (Week 24-28) was observed between the parent and extension study.

Participant flow — Overall Study
MilestoneEteplirsen 30 mg/kgEteplirsen 50 mg/kg
Started66
Completed66
Not completed00

Outcome measures

PrimaryChange From Baseline in the 6 Minute Walk Test (6MWT) at Week 240

This study used a modified version of the 6MWT test procedure described in American Thoracic Society (ATS) 2002 guidelines, specifically adapted for patients with Duchenne muscular dystrophy. The participant was asked to walk a set course of 25 meters for 6 minutes (timed) and the distance walked in meters was recorded. Increases from baseline in 6MWT distance are indicative of improvement and decreases from baseline indicate worsening. Baseline here corresponds to the baseline in the parent study (4658-us-201, NCT01396239).

Time frame:
Parent Baseline and Week 240
Reported as:
Mean · Meters
Change From Baseline in the 6 Minute Walk Test (6MWT) at Week 240
MetersEteplirsen 30 mg/kgEteplirsen 50 mg/kg
Change From Baseline in the 6 Minute Walk Test (6MWT) at Week 240-199.0 ± 113.25-258.0 ± 175.65
PrimaryChange From Baseline in the Percentage of Dystrophin Positive Fibers (PDPF) at Week 48

Dystrophin expression as assessed by percent dystrophin positive fibers was measured by immunohistochemistry (IHC) technique using primary anti-dystrophin antibody. Percent change from baseline is the arithmetic difference of the treatment time point minus baseline divided by baseline calculated for individual subjects. Baseline here corresponds to the baseline in the parent study (4658-us-201, NCT01396239).

Time frame:
Parent Baseline and Week 48
Reported as:
Mean · Percentage of Dystrophin Positive Fibers
Change From Baseline in the Percentage of Dystrophin Positive Fibers (PDPF) at Week 48
Percentage of Dystrophin Positive FibersPlacebo to EteplirsenEteplirsen 30 mg/kgEteplirsen 50 mg/kg
Change From Baseline in the Percentage of Dystrophin Positive Fibers (PDPF) at Week 4837.70 ± 12.60251.69 ± 7.08942.93 ± 13.433

Adverse events

Collected over Parent Baseline up to 240 weeks (cumulative Study 4658-us-201 + 4658-us-202). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eteplirsen 30 mg/kg0/6 (0%)4/6 (66.7%)6/6 (100%)
Eteplirsen 50 mg/kg0/6 (0%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventEteplirsen 30 mg/kgEteplirsen 50 mg/kg
Femur FractureInjury, poisoning and procedural complications3/61/6
ScoliosisMusculoskeletal and connective tissue disorders2/60/6
Tibia FractureInjury, poisoning and procedural complications0/61/6
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/60/6
Most frequent other events
Showing 10 of 200
Most frequent other events
EventEteplirsen 30 mg/kgEteplirsen 50 mg/kg
Procedural painInjury, poisoning and procedural complications5/66/6
Back painMusculoskeletal and connective tissue disorders6/63/6
HeadacheNervous system disorders4/65/6
Nasal congestionRespiratory, thoracic and mediastinal disorders5/62/6
VomitingGastrointestinal disorders5/64/6
ArthralgiaMusculoskeletal and connective tissue disorders5/64/6
NasopharyngitisInfections and infestations4/65/6
ContusionInjury, poisoning and procedural complications4/64/6
Activated partial thromboplastin time prolongedInvestigations0/64/6
Oropharyngeal painRespiratory, thoracic and mediastinal disorders4/64/6

Baseline characteristics

The safety population included all randomized participants who received any amount of study drug.

Age, Continuous
Age, Continuous(years)Eteplirsen 30 mg/kgEteplirsen 50 mg/kgTotal
Mean9.2 ± 0.758.8 ± 1.479.0 ± 1.13
Sex: Female, Male
Sex: Female, Male(Participants)Eteplirsen 30 mg/kgEteplirsen 50 mg/kgTotal
Female000
Male6612
Region of Enrollment
Region of Enrollment(Participants)Eteplirsen 30 mg/kgEteplirsen 50 mg/kgTotal
United States6612
08

Study locations

11 sites
  • Miller Children's Hospital
    Long Beach, California 90806, United States
  • University of Florida Clinical Research Center
    Gainesville, Florida 32610, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Washington University Medical School
    Saint Louis, Missouri 63110, United States
  • Summerwood Pediatrics/Infusacare Medical Services
    Liverpool, New York 13088, United States
  • Levine Children's Hospital
    Charlotte, North Carolina 28203, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Children's Specialty Group, Pediatric Neurology
    Norfolk, Virginia 23510, United States
  • Osceola Medical Center
    Osceola, Wisconsin 54020, United States
09

References and documents

Publications

  • Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E; Eteplirsen Study Group and Telethon Foundation DMD Italian Network. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016 Feb;79(2):257-71. doi: 10.1002/ana.24555. Epub 2016 Jan 8. PubMed 26573217 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2012 to primary completion in Apr 2016, 49 months.

Results were first posted in Jul 2019, 3 years 2 months after primary completion.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 49 months is above that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2012
First posted
Feb 28, 2012
StartActual
Feb 27, 2012
Primary completionActual
Apr 15, 2016
CompletionActual
Aug 16, 2017
Results first posted
Jul 10, 2019
Last update
Mar 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01540409
Responsible party
Sponsor
First posted
Feb 28, 2012
Start date
Feb 27, 2012
Primary completion
Apr 15, 2016
Completion
Aug 16, 2017
Results posted
Jul 10, 2019
Last update
Mar 30, 2020

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eteplirsen

Start the discussion